August 2019 - Promotion of Neomag (magnesium glycophosphate) by Neoceuticals Ltd
Published 14 October 2019
© Crown copyright 2019
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-august-2019/august-2019-promotion-of-neomag-magnesium-glycophosphate-by-neoceuticals-ltd
MHRA received an anonymous complaint by referral from the Prescription Medicines Code of Practice Authority (PMCPA) about a promotional letter for Neomag by Neoceuticals. The complainant alleged that, by instructing GP practices to switch any patients currently prescribed unlicensed magnesium glycophosphate to Neomag, the letter may not promote the rational use of the medicine.
MHRA upheld the complaint. Neoceuticals confirmed that they would not issue material repeating the instruction in future.